Helix Nanotechnologies

Next-generation mRNA platform to solve cancer, COVID and climate.

Operating in healthcare based in Boston, MA, USA; Cambridge, MA, USA, Helix Nanotechnologies was founded in 2013.

Profile

Technology finds information and delivers physical products to us almost instantly. mRNA does the same for biology. At HelixNano, we see a world where treatments are cheap, progress is decentralized, and you can modify biology at the push of a button.

By focusing on mRNA improvements from first principles, we’re getting there faster than we thought. Experiments that used to take months or years can be done in weeks and cost thousands instead of millions. The rate limiting step for our progress is now scientific curiosity.

Rigid hierarchies and top-down decisions will miss the magic. Some of our most powerful technologies started out as side projects of junior team members. At HelixNano, every individual scientist can have a massive impact on the company's direction. And the more diverse our team, the faster we’ll find the really cool ideas.

We've started rolling out some of our new tech — moving a COVID-19 vaccine candidate for the immunocompromised towards the clinic, and testing an intervention with massive environmental impact. But we’re scientists at heart, and team focus is solidly on the horizon.

Within the healthcare space, the company focuses on its core offering rather than a broad product line.

Boston, MA, USA; Cambridge, MA, USA is where the company is located.

Directory data places it at the Winter 2017 stage.

Recorded headcount: 22 employees.

Total disclosed funding stands at about $59.8M.

Website: helixnano.com